Oncolytic Virus Landscape Report 2017: Takeover of BioVex by Amgen in Late 2011, Worth up to US$ 1 Bln, has Woken up the Field and Became a Game Changer - Research and Markets
DUBLIN, Jan 31, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "The Oncolytic Virus Landscape 2017: an Analysis of Pipeline, Stakeholders, Deals, Industry Trends & Opportunities" report to their offering.
This report "The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities" as of January 2017 brings you up-to-date regarding key players, key technologies, Oncolytic Virus projects, business deals and private and public financing rounds. The report analyzes the Oncolytic Virus pipeline and stakeholders in the field, especially among Big Pharma/Biotech and technology companies. The report highlights the value of oncolytic viruses in terms of partnering terms and conditions, venture and private financing and (initial) public offerings.
The field of oncolytic viruses was quite dormant in the first decade of the 2000s, characterized by slow clinical progress due to hyper-cautiousness and low, albeit steady, investments. The takeover of BioVex by Amgen in late 2011, worth up to US$ 1 bln, has woken up the field and became a game changer together with the 2015 approval of the first oncolytic virus Imlygic developed by BioVex in regulated markets. In addition, it was increasingly recognized that oncolytic viruses not only were able to directly lyse cancer cells, but they also "freed" tumor specific neoantigens, indirectly acting as a cancer vaccine.
Optimization of oncolytic viruses is ongoing and new constructs intend to solve some of the open problems regarding the way of administration (intratumoral vs systemic), higher cancer cell specific replication capacity, and longer persistence in vivo. Based on experience with several virus families over the last decades, a few virus families cristallized as well suitable backbones to carry more and more transgenes to express proteins or even single chain antibodies. This would position oncolytic viruses as independent therapeutics and could compete with immuno-oncology compounds and cancer vaccines.
This report has been built in a bottom-up way by desktop search to identify and describe company, product, technology and business/financing profiles which then were evaluated and analyzed with a final outlook describing perspectives with challenges and opportunities.
Key Topics Covered:
1 Executive Summary
2 Introduction & Overview
3 Selection, Design & Construction of Oncolytic Viruses
3.1 Herpes Simplex Virus (HSV) - based Oncolytic Viruses
3.2 Adenoviruses - based Oncolytic Viruses
3.3 Vaccinia Virus - Based Oncolytic Viruses
3.4 Vesicular Stomatitis Virus - based Oncolytic Viruses
3.5 Newcastle Disease Virus - based Oncolytic Viruses
3.6 Various Oncolytic Viruses
4 Profiles of Oncolytic Viruses
4.1 HSV-based Oncolytic Viruses
4.2 Adenovirus-based Oncolytic Viruses
4.3 Vaccinia Virus-based Oncolytic Viruses
4.4 Vesicular Stomatitis Virus-based Oncolytic Viruses
4.5 Newcastle Disease Virus-based Oncolytic Viruses
4.6 Various Oncolytic Viruses
4.7 Stem Cell-delivered Oncolytic Viruses
5 Analysis of Oncolytic Virus Pipeline
5.1 Overview of the Pipeline of Oncolytic Viruses
5.2 Approved and Marketed Oncolytic Viruses
5.3 Late Stage Development of Oncolytic Viruses
5.4 Combination of Oncolytic Viruses with Immune Checkpoint Inhibitors and Other Anti-Tumor Agents
5.5 Armed Oncolytic Viruses
6 Company Profiles
6.1 Pharma & Biotech
6.2 First Generation Oncolytic Virus Companies
6.3 Second Generation Oncolytic Virus Companies
6.4 Third Generation Oncolytic Virus Companies
6.5 Fourth Generation Oncolytic Virus Companies
7 Stakeholder Analysis
7.1 Pharma & Biotech
7.2 First Generation Oncolytic Virus Companies
7.3 Second Generation Oncolytic Virus Companies
7.4 Third Generation Oncolytic Virus Companies
7.5 Fourth Generation Oncolytic Virus Companies
8 Financing & Partnering
8.1 Grants, Credits & Donations
8.2 Venture Capital, Private Equity & Private Placements
8.3 Partnering Deals
8.4 Listing on the Stock Market
8.5 Mergers & Acquisitions
9 Trends & Opportunities
10 References
Companies Mentioned
- Amgen
- Astellas Pharma
- AstraZeneca (MedImmune)
- Bayer
- Benevir Biopharm
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene
- Cold Genesys
- DNAtrix
- Daiichi Sankyo
- Duke University start-up Company
- GSK (GlaxoSmithKline)
- GeneLux
- Green Cross
- Grifols
- IGNITE Immunotherapy
- Jiangsu Hengrui
- Latima
- Lee's Pharma
- Lokon Pharma
- Medigen Biotechnology
- Merck
- Multivir
- Neotropix
- Oncolys BioPharma
- Oncolytics Biotech
- Oncorus
- Orca Therapeutics
- Oryx
- Otsuka Pharmaceutical Co
- Pfizer
- Profectus Biosciences
- PsiOxus
- Replimune
- Roche
- Shanghai Sunway Biotech
- SillaJen
- Sotio
- StemImmune
- StingInn
- TILT Biotherapeutics
- Takara Bio
- Targovax
- TheraBiologics
- Theravir
- Transgene
- Turnstone Biologics
- Unleash Immuno Oncolytics
- VCN Biosciences
- ViraTherapeutics
- Viralytics
- Virttu Biologics (TNK Therapeutics)
- Vyriad
- Wellstat Biologics
- Western Oncolytics
For more information about this report visit http://www.researchandmarkets.com/research/kpdn6b/the_oncolytic
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article